Table 4.

Individual assessment of the enhancement in predictive accuracy associated with each definition of PSA dynamics for prediction of prostate-cancer–specific mortality, after adjustment for the pretreatment PSA level. Concordance indices are comparable only across each row and not comparable row by row as the patients included varied for each definition.

		Concordance Index
	Number of patients	Dynamic Alone	PSA Alone	PSA plus PSA Dynamic	Enhancement* (95% CI)
Doubling Time
MSKCC26	565	0.525	0.688	0.680
Shulman18	561	0.523	0.689	0.681
MD Anderson 216	553	0.511	0.691	0.680
MD Anderson 116	545	0.509	0.688	0.682
Ward21	350	0.547	0.692	0.685
Freedland14	327	0.524	0.707	0.667
Egawa13	210	0.611	0.727	0.738
Trapasso22	194	0.576	0.658	0.661
Stephenson20	135	0.507	0.656	0.649
Hanks15	112	0.601	0.704	0.712
Smith19	59	0.692	0.763	0.798
D’Amico12	40	0.771	0.810	0.803
Velocity
MSKCC26	594	0.582	0.692	0.673
Thompson25	589	0.585	0.693	0.673
D’Amico A4	492	0.601	0.677	0.626	−0.051 (−0.070, 0.003)
D’Amico A >2 ng/mL/yr4	492	0.600	0.677	0.685	0.008 (−0.018, 0.036)
Rozhansky23	369	0.599	0.671	0.619
Sengupta17	327	0.617	0.707	0.671
D’Amico B5	90	0.730	0.773	0.746	−0.027 (−0.059, 0.050)
D’Amico B >2 ng/mL/yr5	90	0.695	0.773	0.776	0.003 (−0.008, 0.033)
Thiel24	82	0.642	0.695	0.667
Smith19	59	0.662	0.763	0.728

^*Enhancement in predictive accuracy (PSA plus PSA Dynamic versus PSA alone) given for PSA dynamics with adjustment for PSA.